Elicio Therapeutics (ELTX) AI Stock Analysis

• Market Cap: $143.24M
• Dividend Yield: N/A
• Average Volume (3M): 77.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: N/A
• EPS Growth: 17.36%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.60
• Shares Outstanding: 17,489,515
• 10 Day Avg. Volume: 85,490
• 30 Day Avg. Volume: 77,231
• PEG Ratio: 0.03
• Price to Book (P/B): -5.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.68
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -143.39
• Enterprise Value/Ebitda: -2.84
• 1Y Price Target: $15.50
• Price Target Upside: 91.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $7.50 ▼(-7.18% Downside)

The score is primarily dragged down by weak financial performance (no revenue, substantial losses, and significant cash burn that increases reliance on external funding). Technical indicators also point to a soft trend with negative momentum. Valuation is difficult to justify on earnings due to a negative P/E and no provided dividend yield.

Positive Factors

Strategic Leadership Change

The appointment of a new CFO with extensive experience in corporate finance and strategy is expected to strengthen Elicio's strategic alignment and financial planning, potentially enhancing the company's ability to advance its immunotherapy platform and achieve clinical milestones.

Clinical Advancements

Advancements in clinical programs, particularly with lead product candidates like ELI-002, are crucial for long-term growth and success in the biotech industry, potentially leading to new revenue streams and partnerships.

Innovative Immunotherapy Platform

Elicio's proprietary Amphiphile platform enhances the potency and durability of immune responses, providing a competitive advantage in the development of cancer vaccines and immune-modulating therapies, which is essential for long-term success in the biotech sector.

Negative Factors

Negative Revenue Growth

Negative revenue growth indicates difficulties in generating sales, which can hinder the company's ability to invest in R&D and expand its market presence, posing a risk to long-term sustainability.

Poor Margins

Consistently poor margins reflect inefficiencies and financial challenges, which can limit the company's ability to reinvest in its operations and achieve profitability, affecting long-term viability.

Reliance on External Financing

Dependence on external financing due to negative cash flows can lead to financial instability and increased risk, as the company may face challenges in securing necessary funding to sustain operations and growth.

Elicio Therapeutics Business Overview & Revenue Model

Company Description

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.

How the Company Makes Money

Elicio Therapeutics makes money primarily through the development and commercialization of its proprietary immunotherapy products. The company generates revenue by partnering with pharmaceutical companies for the co-development and licensing of its technologies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales. Additionally, Elicio may receive funding from grants and research collaborations with academic institutions and government agencies, which contribute to its earnings.

Elicio Therapeutics Financial Statement Overview

Summary

Financials remain very weak: zero revenue, large ongoing losses (TTM net loss ~$45.9M; EBIT loss ~$42.3M), and heavy cash burn (TTM operating and free cash flow about -$38.9M). The balance sheet improved from prior negative equity, but leverage is still meaningful versus a small equity base, keeping funding risk elevated.

Income Statement

The income statement profile remains weak. Revenue is zero in both 2024 (annual) and 2025-09-30 TTM (Trailing-Twelve-Months), while losses are large and persistent (TTM net loss of ~$45.9M; EBIT loss of ~$42.3M). Profitability has not stabilized, and margins are deeply negative, reflecting a business still heavily in investment mode with no meaningful operating leverage visible in the provided periods.

Balance Sheet

The balance sheet shows mixed signals. Leverage is currently elevated with debt of ~$5.3M against equity of ~$3.8M in TTM (Trailing-Twelve-Months), implying a debt load that is meaningful relative to the equity base. A notable positive is the improvement versus 2024 (annual), where equity was negative, suggesting recapitalization and/or balance sheet repair. However, returns on equity are highly negative in TTM (Trailing-Twelve-Months), consistent with ongoing losses and a still-fragile capital structure.

Cash Flow

Cash flow is pressured by heavy cash burn. TTM (Trailing-Twelve-Months) operating cash flow is about -$38.9M and free cash flow is about -$38.9M, indicating the business is funding operations through external capital rather than internally generated cash. There is a reported improvement in TTM free cash flow growth, but cash usage remains substantial and sustained, keeping financing risk elevated.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	28.31M	2.88M
Gross Profit	-866.00K	-1.18M	-1.17M	-1.06M	27.08M	1.06M
EBITDA	-43.68M	-50.27M	-32.97M	-23.55M	-51.92M	-70.63M
Net Income	-45.86M	-51.90M	-35.20M	-28.21M	-26.40M	-80.11M
Balance Sheet
Total Assets	28.28M	28.18M	27.15M	22.66M	96.51M	47.35M
Cash, Cash Equivalents and Short-Term Investments	20.61M	17.62M	12.89M	7.80M	88.76M	34.61M
Total Debt	5.34M	26.04M	6.92M	7.48M	4.66M	85.04M
Total Liabilities	24.47M	39.49M	15.77M	13.75M	15.01M	137.80M
Stockholders Equity	3.82M	-11.31M	11.37M	8.91M	81.51M	-90.45M
Cash Flow
Free Cash Flow	-38.94M	-37.16M	-32.76M	-22.83M	-24.46M	-22.93M
Operating Cash Flow	-38.90M	-37.07M	-32.69M	-22.18M	-23.94M	-22.89M
Investing Cash Flow	-45.00K	-84.00K	-32.00K	-654.00K	-525.36K	-41.00K
Financing Cash Flow	32.06M	42.32M	38.61M	21.20M	19.39M	52.41M

Elicio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Negative. The current price of 8.08 is above the 20-day moving average (MA) of 8.05, below the 50-day MA of 8.20, and below the 200-day MA of 8.60, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.90 is Neutral, neither overbought nor oversold. The STOCH value of 39.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTX.

Elicio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CGEN	56 Neutral	$182.39M	-6.45	-52.95%	―	-88.47%	-1658.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MCRB	50 Neutral	$136.96M	25.17	15.95%	―	448.44%	―
MIST	49 Neutral	$165.23M	-2.19	-260.65%	―	―	3.70%
ELTX	43 Neutral	$143.24M	-2.38	―	―	―	17.36%
SAVA	42 Neutral	$98.55M	-0.93	-85.44%	―	―	-505.96%